Are MBAs Necessary for Start-ups or VC?

Both Sides of the Table

This is part of my ongoing series called “ Start-up Lessons.&#. I was reading Chris Dixon’s blog tonight. I came across this blog post about getting a computer science degree as the best degree for getting into venture capital or working at a VC-backed start up.

Study: Reflexion Health Virtual Therapy System Reduces Rehab Costs

Xconomy

The study, which evaluated Reflexion’s system for patients after total knee replacement surgery, was conducted in conjunction with the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine.

Study 85

Entrepreneurship: Nature vs. Nurture? A Religious Debate

Both Sides of the Table

I grew up believing that human behavior was 20% nature, 80% nurture. There have been many studies done on the topic including looking at twins raised in separate families. There have been studies of adopted children to their natural parents versus the parents that raised them.

What Can You Learn from the 4-Hour Workweek?

Both Sides of the Table

Let me start by saying I’m a huge business book cynic. But Net had told me that he picked up some valuable lessons from the book, so I thought, “WTF? They can travel the world, take classes in interesting subjects, spend time with loved ones or start new hobbies.

Economic Study Ranks San Diego Near Top in Genomics Innovation

Xconomy

An economic impact study of San Diego’s emerging genomics industry counted 115 genomics-related companies operating in the region that directly employ over 10,000 people, and drive about $5.6 After previewing a glimpse of the study’s findings last month , Brady provided.

How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy

Xconomy

Earlier this year, Sarepta bought a startup that spun out of. If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America’s other biomedical hubs.

Study Stakes San Diego’s Claim in Genomics: $292M in 2016 VC Deals

Xconomy

Preliminary findings from an economic impact study show that genomics is emerging as a distinct innovation cluster in San Diego. startupsThe San Diego Regional Economic Development Corp.

Cirius Therapeutics Raises $40M to Expand Ongoing Liver Study

Xconomy

A $40 million transfusion led by Frazier Healthcare Partners and Denmark’s Novo A/S is bringing fresh life to a Michigan biotech working to advance a new experimental drug for treating a type of non-alcoholic fatty liver disease.

Study 62

Countering Cybersecurity Turnover: 57 Companies That Do It Best

Xconomy

What does it take to keep highly skilled cybersecurity employees? Salary and benefits are table-stakes.

Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours

Xconomy

Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the.

Study 77

Doing the Right Things is More Important than Doing Things Right

Both Sides of the Table

Yesterday I wrote a post about top-down versus bottom-up thinking. So they create a task list of all the marketing activities an organization can do: press releases, web site updates, customer case studies, blog posts, daily Tweets, Facebook fan page, attending conferences, etc.

SEM 345

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

Xconomy

After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday. In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.

Top 120 Startup Posts for 2010

SoCal CTO

Some really great stuff in 2010 that aims to help startups around product, technology, business models, etc. Steve Blank , January 25, 2010 10 Tips for Adding Game Mechanics to a Non-Gaming Service - ReadWriteStart , September 21, 2010 Startups & VCs: Learn How to Design, Market, & Eat Your Own. - Forum December 9th Lineup - Startup Houston , November 27, 2010 When to step on the gas and go for it?

X·CON 2018: Photos From Three Innovation Days in November

Xconomy

View the Slideshow On November 4-6, Xconomy organized a meeting of the minds—an elite gathering of leaders in technology, business, healthcare, education, and energy—to discuss and demonstrate the key trends in their fields, heading into next year.

Study 80

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

Xconomy

Biogen’s (NASDAQ: BIIB ) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase 3 study and eviscerated the company’s shares. But he also pointed to moves the company has made to shore up its multiple sclerosis franchise and add drug candidates in other therapeutic areas. The road to every new drug approval is littered with the remains of earlier failures. Biopharmaceutical companies don’t like to talk about the failures.

Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More

Xconomy

The announcement comes less than a month after Boulder, CO-based Array announced positive data from a pivotal study of its combination drug in colorectal cancer. Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma. Array has told investors that its top priority is maximizing the success of the combination, Braftovi and Mektovi.

Study 47

Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests

Xconomy

Beta Bionics, a startup developing a medical device that monitors and manages blood sugar levels in diabetes patients, has closed $63 million to back late-stage clinical tests of its AI-powered technology.

Study 86

With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

Xconomy

The startup, Ambys Medicines, has formed an unusual, broad alliance with Takeda. A new biotech has debuted today aiming to make a variety of treatments for deadly liver diseases.

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

Xconomy

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. The growing epidemic of the fatty liver disease known as NASH, which has no FDA-approved treatment, has led to a frenzied race among drug companies. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 64

Biolinq Adds $4.75M to Advance Glucose Monitoring Biosensor Patch

Xconomy

Biosensor startup Biolinq said Thursday it has raised $4.75 million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device. The San Diego startup.

Study 103

Can AI Tools, $76M Lead BlackThorn to Targeted Pysch Drugs?

Xconomy

The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. The other, for autism, could start a Phase 1 study in 2020.

Tool 77

Patient Network Group Says Majority of Members Want To Keep Obamacare

Xconomy

The study is the second run since January by Cambridge, MA-based PatientsLikeMe, a privately held, for-profit company with an online network of more than 500,000 patients with 2,700 chronic diseases. A U.S.

Study 80

Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More

Xconomy

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Bio Roundup: ICER Eyes Cost, Azar at HHS, Gates’s ALZ Cash & More

Xconomy

That could equal the amount one startup hopes to raise in an IPO to develop drugs for Alzheimer’s and other brain diseases. In our roundup this week, Alzheimer’s disease is in the news, thanks to billionaire Bill Gates and his personal pledge of $100 million toward R&D. If a treatment became available, could our health system handle it? One report says no.

News 42

Angel Funding Advice

Both Sides of the Table

Good idea & plan: You must start with a good idea and a PowerPoint deck (my outline is here , scroll down mid way). And a great product starts with the founder. If you can’t get product released and validated then do user studies. Quick caveats: having fewer investors (3-5) is better than many investors (10-15) and PLEASE make sure you hire a great lawyer who has experience in doing start-ups to avoid pitfalls that will make VC harder down the line.

Angel 252

No Self-Editing: Biohacker Josiah Zayner Can’t Stop Living Out Loud

Xconomy

Of the various forms of the technology, CRISPR-Cas9 is the easiest to use, and it’s already showing up in summer camps and school science labs near you. A handful of drug companies have either begun or will soon begin human clinical studies of medicines that directly alter a patient’s genes. Gene editing has arrived.

Study 64

Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More

Xconomy

While other groups tested other fish oils and found no evidence of concrete cardiovascular benefits , Amarin pressed on with a massive study, bleeding cash for years. Amarin said this week that the REDUCE-IT study showed Vascepa lowered the risk of heart disease, marking a. Six years ago, a biotech called Amarin won FDA approval of a prescription fish-oil pill, Vascepa, because it could lower triglycerides, a type of fat in the blood.

News 55

Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups  

Xconomy

Eisai and partner Biogen released the highly anticipated details of an Alzheimer’s disease study they had already deemed positive, after an initial failure. In one sense, the study was the success they have claimed. The devil is in the details, and key clinical trial results made that abundantly clear this week. A high dose of the drug appeared to have a positive impact on patients, compared to placebo.

Study 55

Xconomy Announces Channel Focused on the Future of Education

Xconomy

It asked leading Xconomists the question: What should students be studying now to prepare for 10 years from now? It is our tenth such subject-specific channel, joining Startups, Health IT, Cleantech, Exome (life sciences), Xperience (consumer tech and society), Fintech, Robotics and A.I.,

Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M

Xconomy

PMV Pharmaceuticals is the latest startup to load up with cash in an attempt to home in on one of the toughest targets in cancer biology: the tumor suppressor protein known as p53. The new cash will help PMV push into human clinical studies, though in its statement the startup didn’t say when those studies might begin.

Help 51

Bio Roundup: GOP Vote-a-Rama, Immunotherapy Setbacks, Pharma Revamps

Xconomy

Two failed cancer studies this week provided a fresh reminder how little researchers and clinicians understand about immunotherapy’s vagaries: why it works for some people and not for others.

Study 60

Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More

Xconomy

Just last month, a startup Tsien cofounded announced a round of funding to push ahead with a fluorescent technology that aims to help surgeons cut out tumors without removing healthy tissue. —Healthcare giant Novartis (NYSE: NOV ) is breaking up its cell and gene therapy R&D group , laying off roughly 30 percent of staff. A man who helped shed light—fluorescent light—on biology died far too early, at the age of 64.

News 49

Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More

Xconomy

Here’s a case study of how fast things can change in biopharma. This week, Bristol-Myers Squibb, Merck, and AstraZeneca all curtailed plans to run additional studies with IDO blockers, adding to a recent, similar decision from Newlink Genetics. For a few years, a type of cancer drug called an IDO inhibitor was all the rage, a promising path to expanding the reach of immunotherapy. Major drug makers were dealing, too.

Edtech Venture Funding Down in 2016, But Still Tops $1B

Xconomy

A recent study by EdSurge , an edtech information firm, shows venture funding for U.S. While we’re looking at venture deal numbers from the past year , let’s consider the education technology industry, which isn’t broken out by sector in the general reports I’ve seen.

Study 60

Startups Are A Remix

InfoChachkie

So they don’t have enough dots to connect, and they end up with very linear solutions without a broad perspective on the problem. Everything Is A Remix – Including Your Startup. Nobody starts out original. “Creativity is just connecting things.

.Net 265